AU2012311483B2 - Combination therapy using immunoglobulin and C1-inhibitor - Google Patents

Combination therapy using immunoglobulin and C1-inhibitor Download PDF

Info

Publication number
AU2012311483B2
AU2012311483B2 AU2012311483A AU2012311483A AU2012311483B2 AU 2012311483 B2 AU2012311483 B2 AU 2012311483B2 AU 2012311483 A AU2012311483 A AU 2012311483A AU 2012311483 A AU2012311483 A AU 2012311483A AU 2012311483 B2 AU2012311483 B2 AU 2012311483B2
Authority
AU
Australia
Prior art keywords
inh
immunoglobulin
administered
ivig
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012311483A
Other languages
English (en)
Other versions
AU2012311483A1 (en
Inventor
Milan Bastian
Xinzhi CHEN
Mark Mattson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
US Department of Health and Human Services
Original Assignee
CSL Behring GmbH Deutschland
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland, US Department of Health and Human Services filed Critical CSL Behring GmbH Deutschland
Publication of AU2012311483A1 publication Critical patent/AU2012311483A1/en
Application granted granted Critical
Publication of AU2012311483B2 publication Critical patent/AU2012311483B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012311483A 2011-09-24 2012-09-21 Combination therapy using immunoglobulin and C1-inhibitor Active AU2012311483B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161538832P 2011-09-24 2011-09-24
US61/538,832 2011-09-24
PCT/EP2012/068643 WO2013041677A1 (en) 2011-09-24 2012-09-21 Combination therapy using immunoglobulin and c1-inhibitor

Publications (2)

Publication Number Publication Date
AU2012311483A1 AU2012311483A1 (en) 2013-05-16
AU2012311483B2 true AU2012311483B2 (en) 2016-03-10

Family

ID=46881067

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012311483A Active AU2012311483B2 (en) 2011-09-24 2012-09-21 Combination therapy using immunoglobulin and C1-inhibitor

Country Status (10)

Country Link
US (1) US10471142B2 (enExample)
EP (1) EP2758076B1 (enExample)
JP (1) JP6190368B2 (enExample)
KR (1) KR101956585B1 (enExample)
CN (1) CN104010656B (enExample)
AU (1) AU2012311483B2 (enExample)
CA (1) CA2848510A1 (enExample)
DK (1) DK2758076T3 (enExample)
ES (1) ES2714999T3 (enExample)
WO (1) WO2013041677A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6109081B2 (ja) 2011-03-09 2017-04-05 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 人工表面との接触を含む医学的手技に伴う投与のためのｆｘｉｉ阻害剤
WO2014131865A1 (en) * 2013-02-28 2014-09-04 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
SI2968434T1 (sl) 2013-03-15 2017-11-30 Shire Viropharma Incorporated, C1-INH sestavki za uporabo pri preprečevanju in zdravljenju hereditarnega angioedema (HAE)
AU2014262890B2 (en) * 2013-05-06 2019-01-31 Takeda Pharmaceutical Company Limited Treatment of Alzheimer's disease subpopulations with pooled immunoglobulin G
HUE041809T2 (hu) * 2013-11-22 2019-05-28 Shire Viropharma Inc Eljárások antitest által közvetített kilökõdés kezelésére szervbeültetéses páciensekben C1-észteráz inhibitorral
DK3157548T3 (da) 2014-06-18 2021-09-06 Csl Behring Gmbh Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom
MX2017010323A (es) * 2015-02-20 2017-12-07 Csl Behring Gmbh Formulaciones farmaceuticas de inhibidor de esterasa c1.
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
EP3493832A1 (en) 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
WO2022251654A1 (en) * 2021-05-28 2022-12-01 West Virginia University Board of Governors on behalf of West Virginia University Mitoneet ligands for use in protection from tissue ischemic reperfusion injury

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075837A2 (en) * 2003-02-21 2004-09-10 Tanox, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
WO2007073186A2 (en) * 2005-12-21 2007-06-28 Pharming Intellectual Property Bv Use of c1 inhibitor for the prevention of ischemia-reperfusion injury
US20100143325A1 (en) * 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2009158A (en) * 1934-08-01 1935-07-23 Ophthalmological Foundation In Ophthalmic ergograph
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4227762A1 (de) 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
EP1216052A1 (en) 1999-09-16 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
EP2233499A1 (en) * 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
BRPI1012082B1 (pt) 2009-05-27 2022-08-16 Takeda Pharmaceutical Company Limited Método para preparar uma composição de igg concentrada a partir de plasma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075837A2 (en) * 2003-02-21 2004-09-10 Tanox, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
WO2007073186A2 (en) * 2005-12-21 2007-06-28 Pharming Intellectual Property Bv Use of c1 inhibitor for the prevention of ischemia-reperfusion injury
US20100143325A1 (en) * 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEUROSCIENCE, NY, US, Vol. 158, No. 3, 6 February 2009 pp 1074-1089 *

Also Published As

Publication number Publication date
KR101956585B1 (ko) 2019-03-11
KR20140075753A (ko) 2014-06-19
JP2014526541A (ja) 2014-10-06
AU2012311483A1 (en) 2013-05-16
EP2758076B1 (en) 2018-12-12
HK1200334A1 (en) 2015-08-07
US20140234293A1 (en) 2014-08-21
US10471142B2 (en) 2019-11-12
CN104010656B (zh) 2016-02-24
ES2714999T3 (es) 2019-05-31
EP2758076A1 (en) 2014-07-30
CN104010656A (zh) 2014-08-27
DK2758076T3 (en) 2019-04-01
WO2013041677A1 (en) 2013-03-28
CA2848510A1 (en) 2013-03-28
JP6190368B2 (ja) 2017-08-30

Similar Documents

Publication Publication Date Title
AU2012311483B2 (en) Combination therapy using immunoglobulin and C1-inhibitor
TWI831106B (zh) 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
US9561263B2 (en) Treatment of inflammatory illnesses with ACE2
KR20170118058A (ko) 혈장 칼리크레인 및 인자 xii에 대한 이중특이성 항체
WO2012174055A1 (en) Wound healing using complement inhibitors
Coccolini et al. Biomedical and nutritional applications of lactoferrin
US20140249087A1 (en) Use of hemopexin to sequester hemoglobin
US20220339233A1 (en) Compositions and methods for preventing recurrence of cancer
JP7351835B2 (ja) 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
US20180117126A1 (en) Treatment of inflammatory illnesses with ace2
Bessette et al. Oral administration of a casein matrix containing β-casofensin protects the intestinal barrier in two preclinical models of gut diseases
HK1200334B (en) Combination therapy using immunoglobulin and c1-inhibitor
CN117100862A (zh) Mif和ripk1在围术期缺血性脑损伤中的应用
JP2000053580A (ja) 全身性紅斑性狼そうの治療におけるペプチド化合物の使用方法
JP7246094B2 (ja) 活性調節剤
EP4082560A1 (en) Methods of treating hypertriglyceridemia or hypertriglyceridemia related diseases
Nanchahal et al. Treatment for dupuytren's disease
HK1230094A1 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
JPH08169845A (ja) ヒト由来アンチトロンビン−ｉｉｉの新規用途
NZ727218B2 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)